Northwest Biotherapeutics (NWBO) Financial Statements
Northwest Biotherapeutics Financial Overview
Northwest Biotherapeutics's market cap is currently $289.96M. The company's EPS TTM is $-0.02; its P/E ratio is -6.80; Northwest Biotherapeutics has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.38M | $ 1.38M | $ 1.93M | $ 1.68M | $ 1.00M |
| Gross Profit | $ -959.00K | $ 1.38M | $ -25.80M | $ 135.00K | $ -19.30M |
| Operating Income | $ -59.91M | $ -66.51M | $ -55.51M | $ -67.18M | $ -52.70M |
| EBITDA | $ -49.67M | $ -73.64M | $ -55.34M | $ -97.46M | $ 184.72M |
| Net Income | $ -61.48M | $ -83.78M | $ -62.60M | $ -105.03M | $ 179.13M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 3.04M | $ 2.17M | $ 2.13M | $ 6.96M | $ 15.17M |
| Total Assets | $ 81.29M | $ 26.73M | $ 27.86M | $ 31.32M | $ 40.16M |
| Total Debt | $ 64.83M | $ 67.44M | $ 45.56M | $ 26.61M | $ 38.26M |
| Net Debt | $ 61.79M | $ 65.27M | $ 43.43M | $ 19.64M | $ 23.09M |
| Total Liabilities | $ 128.86M | $ 105.71M | $ 74.92M | $ 159.43M | $ 164.15M |
| Stockholders' Equity | $ -47.57M | $ -78.98M | $ -46.98M | $ -128.10M | $ -123.99M |
| Cash Flow | |||||
| Free Cash Flow | $ -46.27M | $ -58.03M | $ -57.07M | $ -55.68M | $ -44.31M |
| Operating Cash Flow | $ -44.76M | $ -57.02M | $ -53.64M | $ -52.77M | $ -38.30M |
| Investing Cash Flow | $ -1.81M | $ -1.01M | $ -3.44M | $ -2.90M | $ -6.01M |
| Financing Cash Flow | $ 49.33M | $ 56.78M | $ 52.76M | $ 41.97M | $ 48.13M |
Currency in USD